Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03712228 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT03712228 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 44 participants.
The verdict
NCT03712228, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, placebo-controlled, parallel-arm, phase 2 study to investigate the clinical efficacy, pharmacokinetics, and safety of CSL312 as prophylaxis to prevent attacks in subjects with HAE.
Interventions
- DRUG Placebo
- BIOLOGICAL Factor XIIa antagonist monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2021-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03712228
The ClinicalTrials.gov registry entry for NCT03712228 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03712228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03712228 about?
NCT03712228 is a clinical study titled "A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)". This is a multicenter, randomized, placebo-controlled, parallel-arm, phase 2 study to investigate the clinical efficacy, pharmacokinetics, and safety of CSL312 as prophylaxis to prevent attacks in subjects with HAE.
What is the current status of trial NCT03712228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2018-10-29. Estimated completion is 2021-10-15.
What interventions are being tested in trial NCT03712228?
The interventions under investigation include: Placebo (DRUG), Factor XIIa antagonist monoclonal antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT03712228?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.